cTBS Targeting Cerebellum for Drug-refractory Epilepsy

Drug Refractory Epilepsy Clinical Trial

Official title: Bilateral Continuous Theta Burst Stimulation of Cerebellum for Drug-refractory Epilepsy: A Double Blind, Randomised, Single Centre, Crossover Clinical Trial

Status Completed

Clinical Trial Summary

This study aims to observe the effect and safety of cerebellar continuous θ burst stimulation (cTBS) for drug-refractory epilepsy(DRE), in order to provide a new treatment for DRE and improve the quality of life of those patients. A total of 44 patients with DRE will have cTBS via accurate navigation to bilateral cerebellar dentate nuclei. Patients will be randomised into 2 groups in a crossover trial design to have 2 week periods of cTBS separated by 8 week washout periods, following which the patient will cross over to have the opposite condition for a further 2 week. Frequency and symptoms of seizures, scalp EEG, clinical scores, and QOLIE-31 were assessed at baseline and after 1 and 2 month of treatment.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Drug Refractory Epilepsy
• Drug Resistant Epilepsy
• Epilepsy

• NCT number: NCT05042726
• Study type: Interventional
• Source: Xijing Hospital
• Status: Completed
• Phase: N/A
• Start date: August 2, 2021
• Completion date: August 26, 2022